Issue 057.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Haven's health coaching partner going public. Next week I am open to ideas -- what should E&O dig into? Here's what's happening this week:

• What a busy week. I pulled together The Proteus Digital Health Report after the long-running company filed for Chapter 11 bankruptcy on Monday. There's a bit more on that report below or just head to E&O to read the full 4,400-word report now.
• The other big news this week: On Monday the FDA announced that it had (finally) granted Akili Interactive a De Novo clearance for EndeavorRx (AKL-T01), which is video game-based prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD). Perhaps the most remarkable thing about this move by the FDA is that its database shows it only took TWO MONTHS from the time